For more information, follow us on WeChat


For more information, contact us on WeChat


You can contact us info@ringiertrade.com


Contact Us

86-21 6289-5533 x 269

Suggestions or Comments

86-20 2885 5256


Partnership to offer pre-fillable syringe polymer options

Source:Stevanato Group Release Date:2023-01-26 777
ChemicalPlastics & RubberCompoundingOthersRaw Materials & Compounds
Add to Favorites
Stevanato Group collaborates with Transcoject to provide pre-fillable syringe polymer options for pharma

Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life sciences industries, announced its latest collaboration with Transcoject GmbH, a medical device and pharma packaging solutions company. The collaboration will enable Stevanato Group to add cyclic olefin polymer (COP) and cyclic olefin copolymer (COC) PFS to its existing portfolio of solutions providing added value in the customers’ supply chain.


By integrating Transcoject's technological know-how with Stevanato Group’s capabilities and expertise – in drug containment solutions, manufacturing and market trends - Stevanato Group will be able to offer pre-fillable syringes in glass and in both COP and COC polymers.

Nexa web.jpg


COP and COC pre-fillable syringes may be usable in a wide range of applications, including sensitive biologics, mRNA vaccines, and hyaluronic acid-based drugs. The products’ versatility and customizability can make them ideal for meeting many compliance requirements, and they can be seamlessly integrated into existing fill and finish lines.


The addition of COP and COC pre-fillable syringes will uniquely position Stevanato Group to be able to offer both COC, COP and glass options in the market, empowering customers to select the best-suited solution to fit their needs from multiple options, according to Mauro Stocchi, Chief Business Officer at Stevanato Group.  


The technology is intended to enable a broad range of format options from 0.5ml to 200ml, making it adaptable to customers’ specific requirements. Stevanato Group expects the technology to be ready in 2025 with a first validated product for Luer Lock PFS. In the interim, Transcoject will support customers by providing sampling and the companies also intend to utilise their current capacity to meet demand. A staked-needle PFS version is expected to be launched in the following years.

Nexa2 web.jpg


“With this cooperation we combine the strengths of the two companies by bringing together complementary fields of technologies. We thereby intend to strengthen agility and flexibility in terms of customers benefit. In addition, we expect this collaboration to foster innovation and increase value for our customers. I believe this partnership will strengthen our ability to offer our customers outstanding pharma packaging solutions”, said Dr. Christian von Falkenhausen, CEO of Transcoject GmbH.


The technology will embrace Stevanato Group’s commitment to conducting business under the principles of sustainability by embedding sustainability practices, minimising the consumption of natural resources, and optimizing the efficiency of the manufacturing process.


Stevanato Group will unveil the new COP and COC syringe solutions as Nexa Flex™ at the Pharmapack Europe conference in Paris, France, on February 1-2, 2023, at booth no. F46.



Add to Favorites
You May Like